.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
The transition following a first-episode psychosis (FEP) remission represents a critical phase in psychiatric care. Clinicians and patients often face a difficult choice regarding the long-term use of pharmacotherapy. To address this, researchers have developed a new antipsychotic medication decision aid aimed at facilitating shared decision-making. This tool prioritizes recovery goals like autonomy and social reintegration, which traditional clinical models sometimes overlook. Consequently, the prototype provides a structured framework for patients to navigate the complexities of their treatment journey.
The co-developed prototype utilizes a patient-centered design informed by international standards such as IPDAS and the CHIME framework. It is structured into five essential sections: a decision overview, personal values assessment, a balanced review of risks and benefits, a planning module, and shared real-life experiences. Additionally, the tool includes visual decision exercises that help patients clarify their preferences. Therefore, this antipsychotic medication decision aid serves as more than just an information sheet; it acts as an interactive guide for deep clinical engagement.
Evaluation of the prototype revealed high levels of acceptability among patient partners, caregivers, and healthcare providers. Most users described the resource as relatable and empowering. In contrast to standard care, version 3 of the tool received near-perfect scores for clarity and balance. However, some clinicians expressed concerns regarding time constraints and how to integrate such tools into a busy clinical workflow. Furthermore, while early feedback is promising, the research team emphasizes that pilot testing is necessary to evaluate the aid's impact on treatment satisfaction and long-term outcomes.
The tool aims to support individuals who have achieved remission from first-episode psychosis in making an informed choice to continue, reduce, or stop their antipsychotic medication based on their personal values and clinical evidence.
Yes, the decision aid includes a dedicated section on risks and benefits, providing balanced evidence regarding the potential for relapse versus the reduction of side effects.
A multidisciplinary steering group, including individuals with lived experience, clinicians, and researchers, co-developed the tool using iterative feedback and international patient decision aid standards.
Disclaimer: This content is for informational and educational purposes only and does not constitute medical advice. Always seek the advice of a qualified healthcare provider with any questions regarding a medical condition. Refer to the latest local and national guidelines for clinical practice.
References
1. Béchard L et al. Development of a patient decision aid prototype on the decision to continue, reduce or discontinue antipsychotic medication following remission of first-episode psychosis. BJPsych Open. 2026 May 06. doi: 10.1192/bjo.2026.11034. PMID: 42087272.
2. World Health Organization. Duration of antipsychotic treatment in individuals with a first psychotic episode. mhGAP Guideline Update. 2023.
3. Zisman-Ilani Y et al. Usability and Feasibility of the Antipsychotic Medication Decision Aid in a Community Program for First-Episode Psychosis. Psychiatric Services. 2024;75(8):745-752.
"
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
A new patient decision aid (PDA) prototype helps individuals in FEP remission make informed choices about antipsychotic use through shared decision-making....
4 months ago
Dendritic cells bridge innate and adaptive immunity in myocardial infarction. This review explores their pathological roles, circulating dynamics, novel tolerogenic interventions, and how standard cardiovascular medications modulate dendritic cells to improve post-infarction myocardial repair and patient outcomes.
Today
A premature neonate developed upper limb compartment syndrome after uterine rupture extruded the arm through a scar defect. Conservative management with continuous monitoring yielded complete functional recovery and normal limb growth at 10-year follow-up, highlighting non-operative safety in selected cases.
Today
Atherosclerosis involves extensive glycometabolic reprogramming across immune and vascular cells. This review examines how glycolysis, the pentose phosphate pathway, and lactate-driven epigenetic shifts fuel plaque vulnerability, while highlighting novel therapeutic targets like PFKFB3 and LDHA.
Today
Endoscopic posterior cervical fusion combines minimally invasive decompression, joint preparation, and rigid screw-rod fixation for atlantoaxial pathologies. Early clinical findings demonstrate solid bony union, excellent symptom relief, and minimal soft-tissue morbidity without significant vascular compromise.
Yesterday
The All-India Food Processors' Association has approached the Supreme Court to oppose FSSAI's proposed per-100g benchmark for front-of-pack warning labels, advocating instead for a per-serving threshold. We explore the regulatory showdown, nutritional evidence, and implications for clinical lifestyle counseling.
Today
